Sivane KOSKAS, PhD’s Post

Working on HeLa cells? Take a moment to check out this post—we’ve got insights that might be just what you’re looking for!

🌟 Introducing the new and improved InstiGRO® CHO PLUS: Revolutionizing CHO cell line development! 🌟 In collaboration with UGA Biopharma GmbH, we are proud to present our new Application Note on enhancing clonal outgrowth! 🔬 Why InstiGRO CHO PLUS? The cell culture supplement is designed to accelerate your cell line development with unparalleled cloning efficiency and colony growth. Here’s what sets it apart: ✅ Animal Component Free: Compatible with serum-free cell culture workflows. ✅ Improved Cloning Efficiency: Supports single cell survival to enhance clonal outgrowth. ✅ Optical Clarity: Compatible with imaged-based assurance of clonality. ✅ Easy to use: Simply add to your cloning medium before single cell seeding. 📈 Get Started Today! See how InstiGRO CHO PLUS and UGA Biopharma’s First CHOice® medium can transform your research. Contact us for a free InstiGRO CHO PLUS sample or visit our website for more information. Download the Application Note here: https://lnkd.in/e2mgSves... #AdvancedInstruments #UGABiopharma #Biotechnology #ProteinTherapeutics #ResearchAndDevelopment #InstiGROCHOPLUS #LifeSciences #ClonalOutgrowth #FirstCHOiceMedium #SingleCellSeeding

Always innovating, always improving! Check out the new proteins recently launched by Enzo: - Syndecan-2 (human), (recombinant) (Fc-tag) - PGRP-S (human), (recombinant) (His-tag) - CD202B (human), (recombinant) (Fc-tag) - LOXL2 (human), (recombinant) (His-tag) - CD56 (human), (recombinant) (Fc-tag) - GAS6 (human), (recombinant) (His-tag) - Ephrin Type A receptor 6 (human), (recombinant) (His-tag) - MRC1 (human), (recombinant) (His-tag) - GGT1 (human), (recombinant) (Fc-tag) - KAAG1 (human), (recombinant) (Fc-tag) - Ephrin Type A receptor 5 (human), (recombinant) (Fc-tag)  - APLP2 (human), (recombinant) (His-tag) Looking for another protein? You can find it here: https://lnkd.in/gBwRKjzA #science #protein #researchtools #biotech #biopharma

Being a pioneer in your field is exciting, but it also comes with some unique challenges. When Alltrna started, there was no pre-existing framework for the production of chemically modified tRNAs. Over the years, the team has pioneered many of the processes and technologies to advance our first engineered tRNA medicines towards the clinic. In this insightful interview with David McCall of BioInsights, our Chief Technology Officer William Kiesman talks about what it is like leading such an innovative team and the processes it has developed, including product synthesis and scaling, proprietary analytical techniques to understand impurity profiles and inform downstream purification steps, and other drug design and quality control steps. He also discusses further advancements the field will need, including: 🔹the use of more ecologically sustainable, enzymatic processes to reduce waste 🔹the ligation of smaller oligonucleotides to make bigger, more complex systems 🔹innovations in oligonucleotide delivery to cells 📚Register for free to read the article in Nucleic Acid Insights: https://lnkd.in/grXYeGcn #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #StopCodonDisease #geneticmedicines #programmablemedicines 

Membrane proteins play vital roles in cellular functions, yet their study in native cellular settings poses significant challenges due to the complexity of the cell membrane. Cell-free systems offer a groundbreaking solution, enabling high-yield expression, purification, and reinsertion of MPs or their direct incorporation into membrane mimetic systems like liposomes for functional studies. 👉🏻 Discover our new blog post here about the current challenges and perspectives in proteoliposome research: https://lnkd.in/gjSRnDzT Join us in exploring the future of membrane protein research with cell-free systems and proteoliposomes! 🚀🔬 #MembraneProteins #Biotechnology #CellFreeSystems #Proteoliposomes #ResearchInnovation

How would you describe the RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay? Grant Harradence sums it up in three words: Simplicity, ease of use, and the ability to extract more information. Unlike traditional endpoint assays, RealTime-Glo™ enables continuous monitoring of apoptosis and necrosis, providing deeper insights when you need them. Watch the full case study to see how it’s making a difference in the lab: https://bit.ly/4ha8zng #assays #ADC #biotech

🔍Very interesting article in the September edition of GEN (Genetic Engineering & Biotechnology News, pages 22-24) comparing scale-out vs. scale-up: https://lnkd.in/eEUUQkHD For RNA production, scaling out provides key advantages: 🤸♂️ Flexibility in production scale ✨ Ease of operation 💰 CAPEX savings 🚀 Improved production performance   At Quantoom Biosciences, our RNA production operates in a repeat batch mode: 20mL IVT. All IVT reactions in Ntensify™ midi perform uniformly and with minimized shear forces. Plus, purchasing disposables in bulk helps reduce costs, as they are suitable across all production scales. By choosing scale-out, RNA production is efficient, adaptable, and cost-effective! #RNA #ScaleOut #Ntensify

#EastMabFocus | Featured Product   🔬 How can PDGF Unlock the Potential of Cell Culture?   Platelet-derived growth Factor (PDGF) is a dimeric glycoprotein that can be composed of two A subunits (PDGF-AA), two B subunits (PDGF-BB), or a combination of one A and one B subunit (PDGF-AB). It plays an important role in the regulation of cell growth and division. In particular, PDGF can influence blood vessel formation and the growth of blood vessels from already-existing blood vessel tissue. 🚀 Ready to accelerate your research with PDGF? Contact us and discover more about how it can elevate your cell culture outcomes.   #LifeScience #Biotechnology #Biotech #PDGF #CellCulture #GrowthFactors #TissueEngineering

Accelerating Cell Culture Media Development Using Bayesian Optimization-Based Iterative Experimental Design Here, we have applied a Bayesian Optimization-based iterative framework for experimental design to accelerate cell culture media development for two applications. First, we show this approach yields new compositions of media with cytokine supplementation to maintain the viability and distribution of PBMCs in culture. Second, we applied this framework to optimize the production of three recombinant proteins in K.phaffii cultivations. For both applications, we identified conditions with improved outcomes compared to the initial standard media using 3 to 30 times fewer experiments than other methods such as the Design of Experiments. Subsequently, we also demonstrated the extensibility of our approach to efficiently account for additional design factors through transfer learning. https://lnkd.in/g9c_7ZxK #aspenalert #biotech #bioprocess

Our co-founder and CSO Jan Kubicek had the opportunity to share some insights at Discovery on Target 2024 about one of the biggest challenges in membrane protein research: stabilization. In our talk, we discussed how next-generation NativeMP copolymers are paving the way for more efficient stabilization of membrane proteins into native nanodiscs, preserving their natural environment and functionality. If you’re working in biotherapeutics or are interested in membrane protein research, this approach could be a game changer! Check out the full talk here: https://lnkd.in/eKZ8ngFM